US-based TransCelerate BioPharma is launching three new global initiatives to further advance efficiency in clinical trials and accelerate the development of new medicines: creation of common clinical trial protocol templates, development ...
Tags: TransCelerate, clinical trial, Global Initiative, Cubist Pharmaceuticals
US-based biopharmaceutical firm Cubist Pharmaceuticals has completed the acquisition of Trius Therapeutics, which is focused on the development of antibiotics, for about $704m. The acquisition of Trius brings to Cubist a late-stage ...
Biopharmaceutical firm Cubist Pharmaceuticals is voluntarily recalling four lots of Cubicin (daptomycin for injection) 500mg in 50ml single use vials in the US primarily due to presence of glass particulates. The company said that no ...
Tags: Cubicin Injection, Cubist
Cubist Pharmaceuticals has entered into two separate agreements to acquire Optimer Pharmaceuticals and Trius Therapeutics, as part of the company's Building Blocks of Growth strategy to strengthen its presence in acute care and hospital ...
Cubist Pharmaceuticals has received the US Food and Drug Administration (FDA) fast track status for its late-stage antibiotic candidate ceftolozane/tazobactam in the previously granted Qualified Infectious Disease Product (QIDP) ...
Tags: Cubist, Fast Track Status
Fundacion MEDINA has entered into a contract research collaboration with Cubist Pharmaceuticals to discover novel antibiotics from Cubist's and MEDINA's proprietary and natural product libraries. The alliance will be focused on going ...
Tags: Research Collaboration, Cubist's drug, anti-bacterial drugs